Paper35559366
Risk factors for oxaliplatin-induced hypersensitivity reaction in patients with colorectal cancer.
Song Q and 8 others. Am J Transl Res, 2022. Cited by 9 papers, by iCite.
Cite this record
ConductScience Library. Risk factors for oxaliplatin-induced hypersensitivity reaction in patients with colorectal cancer. Papers, record 35559366. Release papers-2026-11-12-0.1.0, 12 Nov 2026. https://conductscience.org/library/papers/35559366
- Sources
- 11 sources
- Release
- papers-2026-11-12-0.1.0
Paper
PubMed's record of the paper, with iCite's citation figures. No abstract is shown.
- Title
- Risk factors for oxaliplatin-induced hypersensitivity reaction in patients with colorectal cancer.
- PubMed
Topics0
NLM's MeSH indexing of the paper, its major topics first.
None in this release.
References39
The papers the reference list in PubMed's record names, those in our copy of PubMed, in the list's order.
| Order | PMID | Title | Journal | Year | In Papers | Source |
|---|---|---|---|---|---|---|
| 1 | 12888815 | Hypersensitivity reactions related to oxaliplatin (OHP). | Br J Cancer | 2003 | https://conductscience.org/library/papers/12888815 | PubMed |
| 2 | 7249508 | A method for estimating the probability of adverse drug reactions. | Clin Pharmacol Ther | 1981 | https://conductscience.org/library/papers/7249508 | PubMed |
| 3 | 19354063 | Diagnosis and management of hypersensitivity reactions related to common cancer chemotherapy agents. | Ann Allergy Asthma Immunol | 2009 | https://conductscience.org/library/papers/19354063 | PubMed |
| 4 | 25862137 | Hypersensitivity Reactions to Oxaliplatin: Identifying the Risk Factors and Judging the Efficacy of a Desensitization Protocol. | Clin Ther | 2015 | https://conductscience.org/library/papers/25862137 | PubMed |
| 5 | 24417770 | Hypersensitivity to oxaliplatin: clinical features and risk factors. | BMC Pharmacol Toxicol | 2014 | https://conductscience.org/library/papers/24417770 | PubMed |
| 6 | 21524570 | Re-challenging patients with oxaliplatin allergy: the successful use of a standardised pre-medication protocol in a single institute. | Clin Oncol (R Coll Radiol) | 2011 | https://conductscience.org/library/papers/21524570 | PubMed |
| 7 | 11249043 | Idiosyncratic reaction after oxaliplatin infusion. | Ann Oncol | 2001 | https://conductscience.org/library/papers/11249043 | PubMed |
| 8 | 19556337 | Allergic reactions to oxaliplatin in a single institute in Japan. | Jpn J Clin Oncol | 2009 | https://conductscience.org/library/papers/19556337 | PubMed |
| 9 | 11528251 | Hypersensitivity reactions to carboplatin administration are common but not always severe: a 10-year experience. | Oncology | 2001 | https://conductscience.org/library/papers/11528251 | PubMed |
| 10 | 14551506 | Adverse reactions to oxaliplatin: a retrospective study of 25 patients treated in one institution. | Anticancer Drugs | 2003 | https://conductscience.org/library/papers/14551506 | PubMed |
| 11 | 24304429 | A retrospective analysis of the risk factors for allergic reactions induced by the administration of oxaliplatin. | Eur J Cancer Care (Engl) | 2015 | https://conductscience.org/library/papers/24304429 | PubMed |
| 12 | 16282245 | Hypersensitivity reactions to oxaliplatin: experience in a single institute. | Ann Oncol | 2006 | https://conductscience.org/library/papers/16282245 | PubMed |
| 13 | 15648298 | Hypersensitivity Reactions to oxaliplatin: incidence and management. | Oncology (Williston Park) | 2004 | https://conductscience.org/library/papers/15648298 | PubMed |
| 14 | 12478013 | Hypersensitivity reaction to cisplatin during chemoradiation therapy for gynecologic malignancy. | Am J Clin Oncol | 2002 | https://conductscience.org/library/papers/12478013 | PubMed |
| 15 | 22987983 | Prevention and handling of acute allergic and infusion reactions in oncology. | Ann Oncol | 2012 | https://conductscience.org/library/papers/22987983 | PubMed |
| 16 | 12453321 | N9741: a phase III study comparing irinotecan to oxaliplatin-containing regimens in advanced colorectal cancer. | Clin Colorectal Cancer | 2002 | https://conductscience.org/library/papers/12453321 | PubMed |
| 17 | 22099928 | Safety analysis of FOLFOX4 treatment in colorectal cancer patients: a comparison between two Asian studies and four Western studies. | Clin Colorectal Cancer | 2012 | https://conductscience.org/library/papers/22099928 | PubMed |
| 18 | 12712487 | Hypersensitivity and idiosyncratic reactions to oxaliplatin. | Cancer | 2003 | https://conductscience.org/library/papers/12712487 | PubMed |
| 19 | 21448307 | Risk factors for oxaliplatin-induced hypersensitivity reactions in Japanese patients with advanced colorectal cancer. | Int J Med Sci | 2011 | https://conductscience.org/library/papers/21448307 | PubMed |
| 20 | 34745993 | Safety Profile of Oxaliplatin in 3,687 Patients With Cancer in China: A Post-Marketing Surveillance Study. | Front Oncol | 2021 | https://conductscience.org/library/papers/34745993 | PubMed |
Cited by7
The papers in our copy of PubMed whose reference list names this one, newest first. iCite, which reads more sources, counts 9 citations.
| PMID | Title | Journal | Year | In Papers | Source |
|---|---|---|---|---|---|
| 42629496 | Best available evidence for the management of oxaliplatin-induced hypersensitivity reactions, with implications for hepatic arterial infusion chemotherapy (HAIC). | Support Care Cancer | 2026 | https://conductscience.org/library/papers/42629496 | PubMed |
| 42201461 | High-dose dexamethasone and prolonged infusion time prevent oxaliplatin-related hypersensitivity reactions in patients with metastatic colorectal cancer. | Int J Clin Oncol | 2026 | https://conductscience.org/library/papers/42201461 | PubMed |
| 41127694 | Oxaliplatin-Induced Hypersensitivity Reactions Resulting in Respiratory and Cardiac Arrest: A Rare Case. | Clin Case Rep | 2025 | https://conductscience.org/library/papers/41127694 | PubMed |
| 40697651 | Independent risk and protective factors for oxaliplatin-induced hypersensitivity reactions: a retrospective study. | Front Pharmacol | 2025 | https://conductscience.org/library/papers/40697651 | PubMed |
| 40672070 | A real-world study of oxaliplatin-induced hypersensitivity in colorectal cancer treatment based on the pharmacovigilance system in China: a cohort study. | J Gastrointest Oncol | 2025 | https://conductscience.org/library/papers/40672070 | PubMed |
| 39286172 | Huaier relieves oxaliplatin-induced hepatotoxicity through activation of the PI3K/AKT/Nrf2 signaling pathway in C57BL/6 mice. | Heliyon | 2024 | https://conductscience.org/library/papers/39286172 | PubMed |
| 39086615 | Oxaliplatin-associated shock in stage III colorectal cancer patients: real-world evidence in Taiwan. | Ther Adv Drug Saf | 2024 | https://conductscience.org/library/papers/39086615 | PubMed |
Data dates
The date of each source this release read.
- Trials
- 2026-11-12
- Gene search
- 2026-11-11
- Pipelines
- 2026-09-18
None in this release
- Grants
- Trials
- Comments and corrections
- Genes
- Drugs
- Data
Sources 11
- ChEMBL, through Open TargetsCC BY-SA 3.0
- ClinicalTrials.govNo license stated
- HGNCCC0
- iCiteCC BY 4.0
- NCBI GenePublic domain (US government)
- NIH RePORTER's grant and paper linksPublic domain
- Open TargetsCC0 1.0
- PMC's ID filePublic domain (US government)
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0
Each source's terms
- ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ClinicalTrials.govnone stated
- HGNCCC0: https://www.genenames.org/about/license/
- iCiteCC BY 4.0
- NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- NIH RePORTER's grant and paper linksPublic domain (NIH RePORTER)
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- PMC's ID fileNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this paper from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/papers/v1/35559366
GET https://conductscience.org/api/papers/v1/35559366/references?page=2